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Abstract
Background: The benefits of sentinel lymph node biopsy (SLNB) for breast cancer patients with histologically negative axillary
nodes, in whom axillary lymph node dissection (ALND) is thereby avoided, are now established. Low false negative rate,
certainly with blue dye technique, mostly reflects the established high inherent accuracy of SLNB and low axillary nodal
metastatic load (subject to patient selection). SLN identification rate is influenced by volume, injection site and choice of mapping
agent, axillary nodal metastatic load, SLN location and skill at axillary dissection. Being more subject to technical failure, SLN
identification seems to be a more reasonable variable for learning curve assessment than false negative rate.
Methylene blue is as good an SLN mapping agent as Isosulfan blue and is much cheaper. Addition of radio-colloid mapping to
blue dye does not achieve a sufficiently higher identification rate to justify the cost. Methylene blue is therefore the agent of
choice for SLN mapping in developing countries.
The American Society of Breast Surgeons recommends that, for competence, surgeons should perform 20 SLNB but admits that
the learning curve with a standardized technique may be "much shorter". One appropriate remedy for this dilemma is to plot
individual learning curves.
Methods: Using methylene blue dye, experienced breast surgeons performed SLNB in selected patients with breast cancer
(primary tumor < 5 cm and clinically negative ipsilateral axilla). Intraoperative assessment and completion ALND were
performed for standardization on the first 13 of 24 cases. SLN identification was plotted for each surgeon on a tabular cumulative
sum (CUSUM) chart with sequential probability ratio test (SPRT) limits based on a target identification rate of 85%.
Results: The CUSUM plot crossed the SPRT limit line after 8 consecutive, positively identified SLN, signaling achievement of
an acceptable level of competence.
Conclusion: Tabular CUSUM charting, based on a justified choice of parameters, indicates that the learning curve for SLNB
using methylene blue dye is completed after 8 consecutive, positively identified SLN. CUSUM charting may be used to plot
individual learning curves for trainee surgeons by applying a proxy parameter for failure in the presence of a mentor (such as
failed SLN identification within 15 minutes).
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Background
The benefits of sentinel lymph node biopsy (SLNB) in
breast cancer patients with histologically negative axillary
nodes, in whom axillary lymph node dissection (ALND)
is thereby avoided, have now been well established [1].
The risks of lymphedema of the ipsilateral upper limb and
distressing paraesthesiae and pain syndromes associated
with ALND are reduced with consequential improved
quality of life. SLNB is an accurate test of the metastatic
status of axillary nodes [2], particularly when adjacent,
palpably abnormal nodes are also reaped [3], with a false
negative rate not exceeding 5% in properly selected
patients [4] (those with primary breast tumors not exceed-
ing 5 cm [5] and clinically negative axillae) and therefore,
not surprisingly, has also been established as an oncolog-
ically safe and adequate procedure with disease free and
overall survival similar to stage-matched patients having
ALND [6-8].
Methylene blue dye is much cheaper than Isosulfan blue
[9], does not cause hypersensitivity reactions [10] nor
other significant complications (except skin necrosis [11],
avoidable by meticulous injection technique when per-
forming breast conserving surgery) and, most impor-
tantly, is as good as and possibly better at SLN mapping
than Isosulfan blue [9,10,12-16]. Side effects such as blue
discoloration of urine, stool and skin (does not cause tat-
tooing) over the injection site are temporary and benign
[17]. In North America and Europe, it is recommended
that blue dye and radio-tracer mapping be combined as
this approach may yield a higher SLN identification rate
than blue dye alone [5,18-20], although some studies
have not confirmed this advantage [12,16,21]. Radio-
tracer mapping is very expensive (prohibitively so in most
developing countries), cumbersome (requiring time-con-
suming preoperative preparation and increased operating
time), has no significant SLN detection advantage as sin-
gle agent over blue dye [12] (except detection of internal
mammary SLN, an uncommon finding of doubtful clini-
cal and therapeutic significance) and may pose radiation
risk to pathologists handling the nodes [22]. Combina-
tion of the two techniques achieves a range of 0% to 18%
increase in SLN identification rate over blue dye alone
[5,12,16,18-21]. Since 60% of clinically negative axillae
are also pathologically negative [23], combining the
radio-labeled tracer technique with the blue dye tech-
nique stands to benefit only an additional 0 to 11 per 100
women (by way of avoidance of ALND). This seems to be
an unjustifiably high price to pay for such a small addi-
tional benefit, especially since SLNB is not a therapeutic
procedure and does not offer any survival advantage to
patients. Methylene blue dye as a single agent is therefore
well suited to enable surgeons in developing countries to
offer the important technique of SLNB without signifi-
cantly compromising the quality of the test.
The American Society of Breast Surgeons recommends
that, for competence, surgeons should perform 20 SLNB
procedures either under supervised mentoring by an expe-
rienced colleague or followed immediately by completion
ALND [4,24]. It is also recommended that the false nega-
tive rate not exceed 5% and the SLN identification rate not
be less than 85%. Low false negative rate is a reflection of
the high inherent accuracy with which the sentinel node
reflects the metastatic status of axillary nodes, now an
established fact [2], as well as a function of selection of
patients for the procedure who are less likely to harbor
lymph node metastases. SLN identification rate is, like
false negative rate, subject to axillary nodal metastatic
load (patient selection) but also to injection site, volume
and choice of mapping agent, location of the SLN, and,
importantly, the surgeon's skill at dissecting the axilla.
Being more susceptible to technical failure, SLN identifi-
cation therefore seems to be a more reasonable target for
learning curve analysis than false negative rate. Others
agree that SLN identification should be the objective of
the learning process, especially since failure to find the
SLN does not have therapeutically deleterious conse-
quences, ALND being performed in those cases [25].
The American Society of Breast Surgeons admits that the
learning curve for surgeons using a standardized tech-
nique may be "much shorter" than 20 cases [24] but does
not suggest a remedy by way of a reliable method for
assessing individual learning curves. It should hardly be
surprising that experienced breast surgeons can be
expected to master this technique after just a few cases
since, being skilled at ALND, they know how to find the
nodes draining the breast and should therefore have little
difficulty locating a blue sentinel node (radio-tracer map-
ping adds another level of difficulty), as long as patients
are properly selected and the SLN resides within levels I
and II of the axilla. Clearly a method is needed for plotting
learning curves with the capacity to test and predict indi-
vidual performance with reference to a standardized level
of competence.
Cumulative sum (CUSUM) charting is one of a group of
statistical process control methods used by engineers, par-
ticularly in manufacturing, to monitor quality of output
and, with boundary limits set by the sequential probabil-
ity ratio test (SPRT), to indicate when a process is out of
control [26]. Statistical process control methods are now
being used in medicine predominantly for quality control
monitoring [27-29] but more recently, for learning curve
analysis [30-34]. CUSUM plots are an excellent method
for determining learning curves for any procedure with
output variables that can be dichotomized and hold the
promise of individualizing credentialing and competency
certification requirements and ending what has been
called the tyranny of mandatory case numbers.BMC Surgery 2009, 9:2 http://www.biomedcentral.com/1471-2482/9/2
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CUSUM analysis has been applied to the learning curve
for SLNB as a retrospective quality control tool [25] but
not for prospective learning curve analysis. Other learning
curve methodologies have also been applied for SLNB
[35]. In this study, using methylene blue dye as the map-
ping agent, tabular CUSUM control charting is used to
prospectively evaluate the learning curve of individual
surgeons for SLNB and signal achievement of an accepta-
ble, predetermined level of competence.
Methods
The study was approved by the Ethics Committee of the
Ministry of Health of Jamaica. Informed consent was
received from all participating patients. All patients of
either gender presenting to the Cornwall Regional Hospi-
tal (CRH) with breast cancer after implementation of the
study protocol were assessed for eligibility. Participants
were prospectively selected for SLNB if they had an estab-
lished diagnosis of adenocarcinoma of the breast, a Tis, T1
or T2 primary breast tumor (ie, not exceeding 5 cm in
greatest dimension) and a clinically normal ipsilateral
axilla. Completion ALND was performed on all partici-
pants up to and just beyond the end of the learning curves
of both surgeons (13 cases total) as the authors felt that,
this being the first such study in Jamaica, definitive treat-
ment of the axilla during this phase should not differ from
the pre-existing standard of care (a commitment also
given to the Ethics Committee). Subsequent patients were
to have immediate ALND only if the SLN was positive on
intraoperative assessment or could not be identified, and
delayed ALND if an initially negative SLN turned out to be
positive on paraffin section.
After induction of anesthesia, 5 cc of 1% methylene blue
for injection is infiltrated into the subareolar tissue (yields
higher identification rate with blue dye than other sites
[36-38]), except when there is a transverse biopsy scar
across the upper outer quadrant or axillary tail of the
breast, in which case the dye is injected into the paren-
chyma superolateral to the scar (the presence of such a
scar reduces SLN identification rate after subareolar injec-
tion [36,37]). In either case, special care must be taken to
avoid injection into the skin or submammary connective
tissue and muscle. The breast is then massaged for 5 min-
utes.
The surgical site is prepared and the surgeon goes directly
for the SLN via an axillary incision if breast conserving
surgery is the definitive procedure. If mastectomy is the
definitive procedure, the surgeon goes for the sentinel
node after creating the superior flap. All blue nodes and
any node receiving a blue lymphatic channel are sentinel
nodes. After removal of sentinel nodes, adjacent tissue is
palpated and any additional hard or large nodes are also
removed. Total number of nodes removed should usually
not exceed three, otherwise the benefits of the limited dis-
section required for SLNB could be compromised. The fol-
lowing variables are then recorded unto a pre-coded form:
surgeons (surgeon and first assistant), mastectomy versus
breast conserving surgery, site of injection, SLN identified
or not, number of SLNs, Berg's level at which SLN found,
and number of any non-SLN removed. The unfixed nodes
are sent to the pathologist. The operation is then com-
pleted, including ALND (in the first 13 cases and if indi-
cated in the others).
The technique for intraoperative processing of the sentinel
node for touch imprint cytology differed between the 2
pathologists. One pathologist divides the nodes in halves
longitudinally, whilst the other slices them into 2 to 3 mm
transverse sections. The former stains cytology specimen
separately by May Grunwald-Giemsa, Diff-Quik and hae-
matoxylin eosin (H&E) in a shortened regimen and the
latter uses only the H&E technique. Both pathologists
used a similar processing technique and rapid H&E stain-
ing for frozen section. Although the protocol called for
performance of touch imprint cytology and frozen section
on all sentinel nodes, the latter procedure was not always
possible, usually because of equipment failure.
The following variables are recorded by the pathologist on
the original form: SLN cytology (positive or negative),
SLN frozen section, SLN paraffin sections and ALND par-
affin sections. All variables were entered into a database in
STATA version 8 for analysis.
Results
Tables 1 and 2 show the results of the 24 cases performed
by the authors. All patients were female. SLNs were iden-
tified in all of the first 16 consecutive cases and in 6 of the
subsequent 8. In 68% (15/22), only one SLN was identi-
fied. Additional non-sentinel nodes were reaped in 27%
(6/22). Only 1/29 SLN was identified at Berg's level II, the
rest being found at level I. One surgeon (JE) failed to iden-
tify SLN in his 14th and 16th cases. Both had more than 3
nodes involved by metastatic disease in the ALND speci-
men. There were no surgical false negatives among the 13
patients having completion ALND. Of 7 positive paraffin-
embedded SLN in this group, three (43%) were negative
by touch-imprint cytology (and frozen section in one
case). There were no other cytological false negatives
among the subsequent 9/11 cases in which SLN were
identified. In 57% (4/7) of cases with paraffin-positive
SLN, the SLN was the only node involved by metastatic
disease.
Only one patient (case number 3) suffered a significant
complication, with dehiscence and delayed healing of
that part of a partial mastectomy wound which extended
into the peri-areolar region into which methylene blueBMC Surgery 2009, 9:2 http://www.biomedcentral.com/1471-2482/9/2
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had been injected. The wound healed in time for the
patient to start adjuvant chemotherapy one month after
surgery.
The cumulative sum formula (Table 3) was applied to
each surgeon's results and used to create their individual
plots (Figure 1). A sequential probability ratio test (SPRT)
for binary variables [26] was used to calculate upper and
lower limit values, assuming a type 1 error (α) of 0.05, a
type 2 error (β) of 0.2, an acceptable SLN identification
failure rate of 15% and an unacceptable failure rate of
30% (Table 3). The plots of the two surgeons in Figure 1.
are superimposed for 11 cases. Note that the lower SPRT
limit line, based on parameters from Table 3., is inter-
sected after 8 consecutive cases in which the sentinel node
was identified, predicting that there is no statistically sig-
nificant difference between the identification rate of the
surgeons who achieved this number and the 85% identi-
fication rate recommended by the American Society of
Breast Surgeons for the learning phase. An alternate limit
line, based on a type 2 error of 0.1 rather than 0.2 (all
other parameters are the same) is crossed after 12 consec-
utive cases. The upper limit line is omitted from Figure 1.
as it has no relevance to the interpretation of this chart.
Discussion
The unavailability of frozen section for the majority (19)
of cases is not a major shortcoming as touch imprint
cytology is as accurate for intraoperative lymph node
assessment [39], although both methods are limited in
accuracy compared to paraffin sections [40], as confirmed
herein. Insistence on frozen section would also limit the
portability of SLNB to less well equipped hospitals. Suc-
cessful application of ambulatory SLNB [41] with exami-
nation of paraffin-embedded sections and delayed
definitive breast surgery offers improved accuracy of SLN
diagnosis as well as the possibility of performing this tech-
nique even in hospitals without a resident pathologist.
The obvious disadvantage of this latter approach is that all
patients end up with 2 operations instead of only the
Table 1: Profile and results of SLNB and completion ALND.
Case
No.
Surgeons Breast
Surgery
Inj.
Site
No. SLN
ident.
Berg's
Level
Other
Nodes
TIC FS SLN
PARA
ALND
1J E / C V B C S S u b A 1 I 0 + + + -
2J E / C V B C S S u b A 1 I 1 - - + -
3J E / C V B C S S u b A 2 I 0 + + + +
4 JE Mastect SubA 1 I 0 + + + +
5 JE/CV BCS SubA 1 I 0 - ND - -
6 JE BCS SubA 1 I 0 - ND - -
7 JE/CV Mastect SubA 1 I 0 - - - -
8 CV Mastect SubA 1 I 1 - ND + +
9 JE Mastect IntraP 2 I 0 - ND - -
10 JE Mastect SubA 1 II 2 - ND - -
11 CV Mastect SubA 1 I 1 - ND + -
12 CV Mastect SubA 1 I 0 + ND + -
13 JE BCS SubA 2 I 0 - ND - -
BCS – Breast conserving surgery; Mastect – Mastectomy; SubA – subareola; IntraP – Intraparenchymal; TIC – Touch imprint cytology; FS – Frozen 
section; SLN PARA – SLN paraffin sections; ALND – ALND paraffin sections; ND – not done; NA – not applicable
Table 2: Profile and results of SLNB with ALND only if SLN +ve or not found.
Case
No.
Surgeons Breast
Surgery
Inj.
Site
No. SLN
ident.
Berg's
Level
Other
Nodes
TIC FS SLN
PARA
ALND
14 JE Mastect SubA 2 I 0 - ND - ND
15 JE Mastect SubA 2 I 1 - ND - ND
16 JE Mastect SubA 1 I 0 - ND - ND
17 JE Mastect SubA 0 NA 0 NA NA NA +
18 CV Mastect SubA 1 I 0 - ND - ND
19 JE Mastect IntraP 1 I 0 - ND - ND
20 JE Mastect IntraP 0 NA 0 NA NA NA +
21 JE Mastect SubA 2 I 0 - ND - ND
22 CV Mastect SubA 2 I 0 - ND - ND
23 JE Mastect SubA 1 I 0 - ND - ND
24 CV Mastect SubA 1 I 1 - ND - ND
Legend as for Table 1.BMC Surgery 2009, 9:2 http://www.biomedcentral.com/1471-2482/9/2
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small minority with pathological false negative intraoper-
ative node assessment who require delayed ALND.
The presence of metastatic disease in several axillary nodes
of both cases in which no SLN was found implies that they
were poorly selected to begin with and that failure to iden-
tify was probably due to failure of the SLN to take up the
dye [42] rather than failure of technique. Routine preop-
erative sonographic assessment of axillary nodes has the
potential to reduce SLN identification failure for this rea-
son if SLNB is restricted to sonographically negative rather
than clinically negative cases [43].
The case of wound dehiscence was likely due to injection
of dye into or too close to the skin and can be avoided by
careful injection into the central sub-areolar tissue.
There are several formulations of CUSUM charting appli-
cable to learning curve analysis. The simple CUSUM [34],
also called O-E (observed – expected) CUSUM chart, is
based on the formula: Sn = Σ(Xo - Xi)
where Sn is the cumulative sum, Xo is the target compe-
tence level (expressed as a decimal fraction) and Xi = 1 for
a successful outcome and 0 for a failure. Therefore for an
individual successful attempt, the CUSUM decreases by Xo
- 1 and for a failure, it increases by Xo. When the curve
changes its gradient from upwards through horizontal to
decreasing, the learning curve is considered complete
[34]. This is useful for charting learning curves for proce-
dures which take some time to master (that is, for proce-
dures with a high failure rate early on). In charting
procedures with a high success rate early on, as in this
study, the simple CUSUM leads to the conclusion that
there is no learning curve [34] as the plot starts in a nega-
tive direction (the direction of success) and maintains its
gradient.
The tabular CUSUM (also called SPRT chart and log-like-
lihood CUSUM) is in effect a graphical representation of
a hypothesis test comparing each sequential occurrence of
a binary outcome variable to upper and lower limit values
[26,27,31,32]. The test is effectively re-performed for each
event in the sequence, thereby taking into account cumu-
lative past performance, as reflected by the candidate's
position on the plot just prior to the next event. In this for-
mulation, the CUSUM decreases by s for a success and
increases by 1 - s for a failure (see Table 3. for calculation
of s). The null hypothesis for this test states that, for a
given occurrence, the true failure rate is not different from
the target failure rate. When the plot crosses the lower
limit line, the null hypothesis cannot be rejected and this
signals that the predetermined target level of competence
has been achieved. If the plot crosses the upper limit line,
Table 3: CUSUM and SPRT calculations, according to Davies et al [26].
p0 is the acceptable failure rate for SLN identification (0.15)
p1 is the unacceptable failure rate (set at 0.3)
α is the type 1 error (set at 0.05)
β is the type 2 error (set at 0.2)
The CUSUM is increased by 1 - s for a failure and decreased by s for a success.
a = ln [(1 - β)/α] = 2.773
b = ln [(1 - α)/β] = 1.558
P = ln(p1/p0) = 0.693
Q = ln [(1 - p0)/(1 - p1)] = 0.194
s = Q/(P + Q) = 0.219
h0, the lower boundary limit, = -b/(P + Q) = -1.756
h1, the upper boundary limit, = a/(P + Q) = 3.126
CUSUM plots for two surgeons (superimposed for the first  11 cases) Figure 1
CUSUM plots for two surgeons (superimposed for 
the first 11 cases). Primary SPRT limit line is crossed after 
8 consecutive, positively identified SLN and alternate line is 
crossed after 12. Parameters for the primary line are from 
Table 3. and are similar for the alternate line except for a 
type 2 error of 0.1 instead of 0.2. That part of the plot 
beyond either lower SPRT limit line is statistically meaning-
less but is left in place to allow for drawing of other hypo-
thetical limit lines. In practice, the plot may be restarted at 0 
after the SPRT line is crossed, for the purpose of process 
monitoring.BMC Surgery 2009, 9:2 http://www.biomedcentral.com/1471-2482/9/2
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it must either change gradient (as for the simple CUSUM)
or return to a trailing lower limit line placed at a distance
below the upper line equal to the distance from the X-axis
to the original lower limit line, before the learning curve
is considered complete [31]. In a recent variation of the
tabular CUSUM, the plot is not allowed to rise above the
X-axis and the learner is therefore punished less severely
for an early sequence of failures [44]. Limit lines may be
calculated using the method advocated by Davies et al
[26], as was done in this study, or the log-likelihood
method advocated by Wald [28].
For complex procedures, the score for each attempt is risk-
adjusted by multivariable regression and then applied to
an SPRT CUSUM chart [30,45,46]. Calculation of SPRT
limits in these risk-adjusted CUSUM charts is more com-
plex than in the preceding type of chart.
The output of formulas for the tabular CUSUM are subject
to manipulation, and therefore the values for acceptable
failure rate, unacceptable failure rate, type 1 error and type
2 error must be chosen carefully, although subjectivity
cannot be completely avoided. Acceptable and unaccept-
able failure rates are usually set by consensus or conven-
tion. Acceptable failure rate should not be set so low that
only a few gifted surgeons with perfect patient selection
can achieve it. Unacceptable failure rate should be set at a
level above which either the effectiveness (for procedures
without serious consequences) is below average or the risk
(for procedures with serious consequences) above aver-
age. Type 1 error should be set low (maximum 0.1) if we
do not wish to falsely identify a competent surgeon as
being incompetent [47] (that is, falsely assuming that
there is a difference from the target value when none
exists). Conversely, type 2 error should be set low if we
worry about falsely identifying an incompetent surgeon as
competent (that is, falsely assuming that no difference
exists from the target value when one exists). In practice,
type 2 error should not be set too low if the procedure is
easy to learn and if the consequences of failure are not
serious.
Table 4. indicates the different numbers of consecutively
successful cases required to cross the lower SPRT limit line
for different combinations of acceptable and unaccepta-
ble failure rates and type 1 and type 2 error. It also indi-
cates the total number of cases required to cross the limit
line after 3 failures (the effect of failures on the number of
cases required to cross the limit line is independent of
where they occur), the number allowed by the American
Society of Breast Surgeons in their recommended 20 cases.
For a technically more difficult operation or for proce-
dures with more serious consequences for failure than
those for failure to identify a SLN, it could be successfully
argued that both β and p1 should be set lower than 0.2 and
0.3 respectively. Given that SLNB using methylene blue
dye is an easy operation and that the consequence of fail-
ure to identify the SLN simply results in a possibly unnec-
essary ALND, which is still the standard of care, we do not
believe that our choice of 0.2 for β is too high. Studies
have reported SLN identification failure rates with blue
dye of 0.25 [5] and 0.27,[48], and therefore, we also
believe that our choice of unacceptable failure rate of 0.3
is reasonable. Conversely, although the literature suggests
that SLN identification rate can be as high as 95% and
even higher, it would be a mistake to set the acceptable
failure rate for the learning curve at 0.05 since this
assumes perfect selection of patients and perfect tech-
nique.
The tabular CUSUM applied herein is excellent for plot-
ting the learning curve of trainee surgeons being taught to
perform SLNB. All that is required is a proxy measure for
failure to identify the SLN in the presence of a mentor,
such as failure to find the SLN within a specified time, say
15 minutes. Figure 2. (see also Table 4.) is an illustration
of how the CUSUM plot behaves in the hypothetical sce-
nario where the trainee surgeon fails to identify sentinel
nodes in the 1st, 6th and 12th cases. Applying the parame-
ters from Table 3, 22 cases would then be required to cross
the lower limit line and signal the end of the learning
curve, a number marginally higher than the 20 cases rec-
ommended by the American Society of Breast Surgeons
Table 4: Number of consecutive and total cases required to cross the lower limit line for different combinations of acceptable (p0) and 
unacceptable (p1) failure rates, type 1 error (α) and type 2 error (β).
Total no. cases, assuming 3 failures No. consecutive cases, assuming no failures p0/p1 α/β
97 55 0.05/0.1 0.05/0.05
84 42 " 0.05/0.1
46 29 " 0.05/0.2
49 27 0.1/0.2 0.05/0.05
43 21 " 0.05/0.1
36 13 " 0.05/0.2
29 15 0.15/0.3 0.05/0.05
27 12 " 0.05/0.1
22 8 " 0.05/0.2BMC Surgery 2009, 9:2 http://www.biomedcentral.com/1471-2482/9/2
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for a similarly allowed failure rate of 3 cases. This latter
observation provides further support for the reasonable-
ness of our choice of parameters.
Conclusion
Methylene blue dye is an accurate and cost-effective single
agent for sentinel lymph node mapping in breast cancer.
Sentinel node identification rate is a more reasonable tar-
get for assessment of learning curves of surgeons than is
false negative rate. Application of a tabular CUSUM chart,
with SPRT limit values based on a target identification rate
of 85%, and a reasonable choice of other parameters,
demonstrates that experienced breast surgeons have com-
pleted the SLNB learning curve after 8 consecutive success-
ful attempts using methylene blue. This type of learning
curve analysis can be readily applied to trainee surgeons
by using a proxy measure for failure in the presence of a
mentor, such as failure to identify the SLN within 15 min-
utes. Using the same parameters, a trainee surgeon
allowed 3 failures requires 22 cases to complete the learn-
ing curve.
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